Overview

Ark Animal Health develops new veterinary therapeutic solutions—from breakthrough technologies—to address unmet severe healthcare needs of companion animals. A fully owned subsidiary of Sorrento Therapeutics, Ark was formed in 2014 to bring to the companion animal market innovative solutions issued from Sorrento’s human research and development activities. Our lead development program (ARK-001) is a single-dose resiniferatoxin (RTX) sterile injectable solution. ARK-001 has received FDA CVM (center of veterinary medicine) MUMS (minor use/minor species) designation for the control of bone cancer pain in dogs. Conditional approval is expected by late 2018. Other projects include additional indications for RTX in areas such as chronic articular pain in companion animals, neuropathic pain in horses, and idiopathic cystitis in cats. We are also exploring development opportunities in the areas of infectious diseases or potential new approaches to cancer treatment (early stage). Core values • We never forget that patients are waiting on us • We deliver work we can be proud of • We believe kindness is a strength • We thrive on building professional karma Vision Through our efforts, the convenience, accessibility, and effectiveness of pet therapies will make quantum leaps. Our solutions will lead to new standards and set veterinary best practices for years to come.